Randomized comparative single blinded clinical trial on the effectiveness and safety of microneedling in the treatment of androgenetic alopecia.

Hospital São Paulo0 个研究点开始时间: 2020年5月26日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Signature of Written Informed Consent Form and Authorization for Photographs Term prior to any study procedure; men aged between 18 and 60 years, in good health; Clinical diagnosis of moderate male androgenet alopecia (Stage IIIa-IV of the Norwood-Hamilton Scale) with disease onset time less than 10 years; accordance with the conditions of the study, ability to understand and strictly follow the therapeutic guidelines received and availability to attend periodic evaluations.

•Men who do not agree with the conditions of the study or who are unable to understand and strictly follow the therapeutic guidelines received, are not available to attend periodic evaluations or refuse to sign the Written Informed Consent Form and Authorization for Photographs Term; patients suffering from other alopecias, including telogen effluvium; patients with mild disease (stages I and II) or severe disease (stages V to VII of the Norwood-Hamilton Scale); patients who have androgenetic alopecia for more than 10 years; previous use of finasteride or dutasteride in the last 6 months; patients with a current or previous history of malignant or pre-malignant tumors of the scalp; patients that suffer from allergic contact dermatitis to propylene glycol (minoxidil vehicle), minoxidil, tattoo ink, topical or local anesthetic; patients that have dermatoses that may worsen due to the procedure and interfere with the evaluation, such as psoriasis, vitiligo; patients receiving chemotherapy, radiation therapy, corticosteroids or other immunosuppressants.

发起方